BMS received positive EU CHMP opinion for Nivo as an Adj treatment for Melanoma

Merck received positive EU CHMP opinion for Pembro + Trastuzumab + Chemo for Gastric Cancer

The China NMPA accepts sNDA for Junshi Biosciences Toripalimab as the 1L treatment for ES-SCLC

Merck’s Pembro plus Chemoradiotherapy demonstrated encouraging PFS benefits in newly diagnosed Cervical Cancer